Clinical trials: Epithelial Ovarian Cancer, open to volunteers
Ovary Neoplasm, Ovarian Cancer
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian…
- Conditions
- Ovary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent
- Trial name
- NCT06305299
- Testing
- iC9-CAR.B7-H3 T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of liposomal irinotecan combined with enlonstobart in patients with platinum-resistant recurrent ovarian…
- Conditions
- Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers, Epithelial Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07591831
- Testing
- Liposomal Irinotecan
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Epithelial Ovarian Cancer
Sentinel Lymph Node Mapping in Early-Stage Epithelial Ovarian Cancer Surgery
This prospective study aims to evaluate the feasibility and diagnostic performance of sentinel lymph node (SLN) mapping using indocyanine green (ICG) in patients undergoing surgery for early-stage epithelial ovarian cancer.
- Trial name
- NCT07593339
- Testing
- Sentinel Lymph Node Mapping, Indocyanine Green
- Volunteers
- 30 people
- Sponsor
- Başakşehir Çam & Sakura City Hospital
Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial…
- Trial name
- EB-DUALNK-OV (NCT07589543)
- Testing
- EB-DUALNK, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Epithelial Ovarian Cancer
Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer
Background: Previous findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant.
- Trial name
- NCT05284552
- Testing
- Tinzaparin Injectable Solution
- Where
- 8 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- University Hospital, Linkoeping
End of Life, Cancer
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
- Trial name
- NCT05297734
- Testing
- Receive technology-based supportive cancer care, Receive redesigned team-based supportive cancer care
- Where
- 17 sites in United States
- Volunteers
- 2,996 people
- Sponsor
- Stanford University
Solid Tumor, Epithelial Ovarian Cancer
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.
- Conditions
- Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- MUIR (NCT04516447)
- Testing
- Azenosertib, Carboplatin, Pegylated liposomal doxorubicin
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 172 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Advanced Epithelial Ovarian Cancer, Peritoneal Carcinomatosis
Intensification Treatment of Ovarian Cancer by PIPAC
The goal of this clinical trial is to learn whether repeated cisplatin-based PIPAC added to standard TC chemotherapy can improve outcomes in women aged 18-75 years with newly diagnosed FIGO IIIB-IIIC epithelial ovarian cancer and…
- Trial name
- PrimPIPAC (NCT07514494)
- Testing
- PIPAC
- Where
- Russia
- Volunteers
- 160 people
- Sponsor
- Moscow Regional Oncological Dispensary
Ovarian Cancer, Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer
- Trial name
- NCT06366490
- Testing
- Innocell Autologous Cellular Immunotherapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- PhotonPharma, Inc.
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel…
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- ERADIC8 (NCT06395519)
- Testing
- ETX-19477
- Where
- 14 sites in United States
- Volunteers
- 120 people
- Sponsor
- 858 Therapeutics, Inc.
Epithelial Ovarian Cancer
Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1)
Imaging evaluation was performed every 3 months (± 7 days) from enrollment, and real-time examination was performed if new lesions were suspected.
- Trial name
- NCT07495397
- Testing
- Daphne Extract Capsules
- Where
- China
- Volunteers
- 98 people
- Sponsor
- The First Hospital of Jilin University
Ovarian Cancer, Fallopian Tube Cancers
Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer
Efficacy and safety of Benmelstobart combined with Anlotinib and oral metronomic Cyclophosphamide in the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (BACON study) in China
- Conditions
- Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- BACON (NCT07489300)
- Testing
- Benmelstobart in combination with Anlotinib and oral metronomic Cyclophosphamide
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies
- Trial name
- DUAL-OV-CAR-NK (NCT07480954)
- Testing
- Dual-target CAR-NK cell product, Lymphodepleting chemotherapy, Standard supportive care
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
HRD-negative Epithelial Ovarian Cancer
A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer
This is a single-center, open-label, dose-escalation, multiple-dose investigator-initiated exploratory study designed to evaluate the safety, tolerability and preliminary efficacy of tumor neoantigen-pulsed autologous dendritic…
- Trial name
- YS247 (NCT07455071)
- Testing
- Tumor Neoantigen-Sensitized Autologous Dendritic Cell Injection (YS247)
- Volunteers
- 9 people
- Sponsor
- Peking University Third Hospital
Ovarian Cancer, Epithelial Cancer
The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer
The PROOV study is an open-label, monocenter, single-arm, prospective phase I/II trial with a safety lead-in, evaluating the feasibility of combining PARPi with HIPEC in stage III EOC patients.
- Conditions
- Ovarian Cancer, Epithelial Cancer, Fallopian Tube Cancer
- Trial name
- PROOV (NCT07460180)
- Testing
- Olaparib
- Where
- Netherlands
- Volunteers
- 55 people
- Sponsor
- The Netherlands Cancer Institute
Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
This is a prospective, open-label, single-arm, multicenter exploratory clinical study designed to evaluate the efficacy and safety of iparomlimab/tuvonralimab (QL1706), a bispecific antibody targeting programmed cell death…
- Trial name
- NCT07454018
- Testing
- Iparomlimab/Tuvonralimab
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Epithelial Ovarian Cancer
Determining Prognostic Immune Markers in Patients With Ovarian Cancer
The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).
- Trial name
- IMPrOVE (NCT03862677)
- Testing
- No intervention
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Leiden University Medical Center
Ovarian Cancer
Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)
Primary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)
- Trial name
- FOCUS / KOV-04 (NCT05827523)
- Testing
- Cisplatin
- Where
- 10 sites in South Korea
- Volunteers
- 520 people
- Sponsor
- National Cancer Center, Korea
Ovarian Epithelial Cancer
Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer
Study to evaluate the diagnostic precision of ICG and 99mTc nanocolloid albumin in sentinel lymph node detection in early ovarian epithelial cancer.
- Trial name
- Melisa-II (NCT05937620)
- Testing
- 99mTC nanocolloid albumin injection, ICG injection
- Where
- Spain
- Volunteers
- 62 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT06469281
- Testing
- 27T51, Cemiplimab, Bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Regeneron Pharmaceuticals